Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity
Pyrazolopyrimidine compounds, methods of use, and processes for making compounds with anti-Mer tyrosine kinase activity comprising Formula I, II, III, IV, or a pharmaceutically acceptable composition, salt, isotopic analog, or prodrug thereof, are provided. The pyrazolopyrimidine compounds described herein have Mer tyrosine kinase (MerTK) inhibitory activity and are useful as anti-infective agents, immunostimulatory and immunomodulatory agents, anti-cancer agents (including against MerTK −/− tumors and ITD and TKD mutant forms of Acute Myeloid Leukemia (AML)), and as adjunctive agents in combination with chemotherapeutic, radiation or other standard of care for neoplasms.
1. A method for treating a host with an infectious disease, comprising administering an effective amount of the following compound:
or a pharmaceutically acceptable salt, thereof.
2. The method of claim 1 , wherein the infectious disease is a viral infection.
3. The method of claim 1 , wherein the infectious disease is a bacterial infection.
4. The method of claim 2 , wherein the virus is selected from the group consisting of a Flavivirus, Hepacivirus, Pegivirus, Pestivirus, Filovirus, Togavirus, Coronavirus, Orthomyxovirus, Paramyxovirus, Calicivirus, and Lentivirus.
5. The method of claim 2 , wherein the virus is Chikungunya.
6. The method of claim 2 , wherein the virus is HCV.
7. The method of claim 2 , wherein the virus is HIV.
8. The method of claim 3 , wherein the bacterial disease is selected from the group consisting of Escherichia coli, Staphylococcus aureus, Enterococcus faecalis , and Streptococcus pneumoniae.
9. A method for treating a host with a medical disorder in need of immunostimulatory adjunctive therapy in combination with a direct acting drug for the medical disorder, comprising administering an adjunctively immunostimulatory effective amount of the following compound:
or a pharmaceutically acceptable composition or salt thereof.